secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2022-10-26T23:59:59+00:00
Accession:  0000917520-22-000051
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences reports Q3 2022 GAAP EPS $0.60, adjusted EPS $0.86; raises FY adjusted EPS guidance
--------------------------------------------------------------------------------

- Q3 revenues $385M (-0.4% reported, +3.5% organic); GAAP EPS $0.60 (vs $0.51), adjusted EPS $0.86 (flat YoY).
- Codman Specialty Surgical rev $249.8M (-2.6% reported, +1.6% organic); Tissue Technologies rev $135.4M (+3.9% reported, +7.2% organic).
- Raised FY2022 adjusted EPS guidance to $3.29-$3.33; reaffirmed rev $1,551M-$1,563M with organic growth 3.7%-4.5%.
- Completed TWC divestiture to Gentell for $28.8M ($27.8M cash + $1M contingent consideration).
- CereLink recall provision $1.5M, rework $0.8M; return-to-market expected 1H2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000051/0000917520-22-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000051/iart-20221026.htm
  HTML page:      https://secwatch.observer/filing/0000917520-22-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer